Customer Publication

Berberine Maintains the Neutrophil N1 Phenotype to Reverse Cancer Cell Resistance to Doxorubicin

Authors: S. Zhang et al.

Journal: Frontiers in Pharmacology (2020)

Institution: Henan University

Research Areas: Frontiers in Pharmacology

Cell Lines: HL-60 (Human acute promyelocytic leukemia)

Summary: Chemotherapy is one of the main treatments for cancer patients. However, some patients develop chemotherapeutic agent resistance, thus impeding treatment efficiency. One of the hypotheses is that chemotherapeutic resistance and immune responses are related to each other, however, the relationship between them is still unclear. In this study, Sh. Zhang with colleagues have explored the neutrophil's contribution to chemotherapeutic resistance and berberine-regulated cancer cell sensitivity to doxorubicin (DOX). Authors have shown that DOX alone induces HL-60 cell differentiation to N2 type neutrophils and induces chemotherapeutic resistance. When DOX is administered in combination with berberine, HL-60 cells differentiated into N2 type neutrophils and stimulated HL-60 cell immune clearance. In this study, authors have used HoloMonitor M4 to evaluate HL-60 cell differentiation to N1 and N2 type neutrophils by evaluating different phenotypic characteristics in means of morphology and motility.

Keywords: HoloMonitor M4, cell morphology and cell movements, berberine, doxorubicin, neutrophil phenotype, carcinogenesis, chemotherapeutic resistance

Read the article …

Phase Holographic Imaging PHI AB
Skiffervägen 48
224 78 Lund
+46 46 38 60 80

Phase Holographic Imaging PHI Inc.
265 Franklin Street Suite 1702
Boston, MA 02110
+1 617-963-5150


VAT: SE556542781101

Securities Identification

ISIN: SE0005504636
LEI: 549300JZR79QYESM6296

HoloMonitor® is a registered trademark
Copyright © 2012-2021
Phase Holographic Imaging PHI AB

Phase Holographic Image logo in white

PHI Theme 3.12.2